Research Article
Open access
Published on 15 January 2025
Download pdf
Wu,Z. (2025).Wnt/β-Catenin Signaling in Intestinal Cancers: Mechanisms, Therapeutic Targets, and Treatment Strategies.Theoretical and Natural Science,90,68-75.
Export citation

Wnt/β-Catenin Signaling in Intestinal Cancers: Mechanisms, Therapeutic Targets, and Treatment Strategies

Zixuan Wu *,1,
  • 1 Qingdao Academy, Tsingtao, China

* Author to whom correspondence should be addressed.

https://doi.org/10.54254/2753-8818/2025.GU20453

Abstract

Intestinal cancers are always hazardous due to its high morbidity and mortality. Currently, it is known that an error in the Wnt/β-catenin pathway is an essential cause of intestinal cancers. After the inhibitors and markers involved in it are especially studied, targeted therapy has already been considered by the scientists. However, there is only overall understanding in Wnt/β-catenin pathway with many detailed mechanisms uncleared, thus no treatments can be put into practice. This article analyses proteins and factors which have the potential of being used as targets of targeted therapy. Besides, essential inhibitors, such as NEDD4 and E7386, of the Wnt/β-catenin pathway and how lack of them lead to oncogenesis are introduced. Furthermore, the possibility and examples of targeted medicine is discussed. This review offers a wider view of the entire mechanism of intestinal cancers spurred by Wnt/β-catenin pathways. The article encouraged further research in variable stages, and new breakthrough is purposed for therapy based on the Wnt/β-catenin pathway

Keywords

Wnt/β-catenin pathway, colorectal cancer, crypt, intestine

[1]. International Agency for Research on Cancer. (n.d.). Global Cancer Observatory. Lyon. Retrieved [15 12 2024], from https://gco.iarc.who.int/today

[2]. Siegel, R. L., Giaquinto, A. N., & Jemal, A. (2024). Cancer statistics, 2024. CA: A Cancer Journal for Clinicians, 74(1), 12-49.

[3]. Nusse, R., & Varmus, H. E. (1982). Many tumors induced by the mouse mammary tumor virus contain a provirus integrated in the same region of the host genome. Cell, 31(1), 99–109.

[4]. Liu, J., Xiao, Q., Xiao, J., Niu, C., Li, Y., Zhang, X., Zhou, Z., Shu, G., & Yin, G. (2022). Wnt/β-catenin signalling: Function, biological mechanisms, and therapeutic opportunities. Signal Transduction and Targeted Therapy, 7(1).

[5]. Comprehensive molecular characterization of human colon and rectal cancer. (2012). Nature, 487(7407), 330–337.

[6]. Kusserow, A., Pang, K., Sturm, C., Hrouda, M., Lentfer, J., Schmidt, H. A., Technau, U., Von Haeseler, A., Hobmayer, B., Martindale, M. Q., & Holstein, T. W. (2005). Unexpected complexity of the Wnt gene family in a sea anemone. Nature, 433(7022), 156–160.

[7]. Rios-Esteves, J., & Resh, M. D. (2013). Stearoyl CoA desaturase is required to produce active, lipid-modified Wnt proteins. Cell Reports, 4(6), 1072–1081.

[8]. He, X., Semenov, M., Tamai, K., & Zeng, X. (2004). LDL receptor-related proteins 5 and 6 in Wnt/β-catenin signaling: Arrows point the way. Development, 131(8), 1663–1677.

[9]. Janda, C.Y., Dang, L.T., You, C., Chang, J., De Lau, W., Zhong, Z.A., Yan, K.S., Marecic, O., Siepe, D., Li, X., Moody, J.D., Williams, B.O., Clevers, H., Piehler, J., Baker, D., Kuo, C.J., & Garcia, K.C. (2017). Surrogate Wnt agonists that phenocopy canonical Wnt and β-catenin signalling. Nature, 545(7653), 234–237.

[10]. Bilic, J., Huang, Y., Davidson, G., Zimmermann, T., Cruciat, C.-M., Bienz, M., & Niehrs, C. (2007). Wnt induces LRP6 signalosomes and promotes Dishevelled-dependent LRP6 phosphorylation. Science, 316(5831), 1619–1622.

[11]. Muñoz-Castañeda, J.R., Rodelo-Haad, C., Pendon-Ruiz de Mier, M.V., Martin-Malo A., Santamaria R., & Rodriguez M.(2020). Klotho/FGF23 and Wnt signaling as important players in the comorbidities associated with chronic kidney disease.Toxins, 12(3),185.

[12]. Tanksley JP , Chen X , Coffey RJ . (2013). NEDD4L is downregulated in colorectal cancer and inhibits canonical WNT signaling.PLoS ONE, 8: e81514.

[13]. Novellasdemunt L , Kucharska A , Jamieson C , Prange‐Barczynska M , Baulies A , Antas P , Van Der Vaart J , Gehart H , Maurice M.M , & Li V.S.(2019). NEDD4 and NEDD4L regulate Wnt signalling and intestinal stem cell priming by degrading LGR5 receptor.The EMBO Journal,39(3).

[14]. Li B , Lee C , O’Connell J.S , Antounians L , Ganji N , Alganabi M , Cadete M , Nascimben F , Koike Y , Hock A , Botts S.R , Wu R.Y , Miyake H , Minich A , Maalouf M.F , Zani-Ruttenstock E , Chen Y , Johnson-Henry K.C , De Coppi P , Pierro A .(2020). Activation of Wnt signaling by amniotic fluid stem cell-derived extracellular vesicles attenuates intestinal injury in experimental necrotizing enterocolitis.Cell Death and Disease,11(9).

[15]. Niño D.F , Sodhi C.P , Egan C.E , Zhou Q , Lin J , Lu P , Yamaguchi Y , Jia H , Martin L.Y et al.(2016). Retinoic Acid Improves Incidence and Severity of Necrotizing Enterocolitis by Lymphocyte Balance Restitution and Repopulation of LGR5+ Intestinal Stem Cells.Shock,47(1),22–32.

[16]. Siggers J et al.(2013). Postnatal amniotic fluid intake reduces gut inflammatory responses and necrotizing enterocolitis in preterm neonates.AJP Gastrointestinal and Liver Physiology,304(10),G864–G875.

[17]. McCulloh C.J et al.(2018). Treatment of experimental necrotizing enterocolitis with stem cell-derived exosomes.Journal of Pediatric Surgery,53(6),1215–1220.

[18]. Zani A et al.(2013). Amniotic fluid stem cells improve survival and enhance repair of damaged intestine in necrotising enterocolitis via a COX-2 dependent mechanism.Gut,63(2),300–309.

[19]. McCulloh C.J et al.(2017). Evaluating the efficacy of different types of stem cells in preserving gut barrier function in necrotizing enterocolitis.Journal of Surgical Research,214:278–285.

[20]. Augustin H.G & Koh G.Y.(2017). Organotypic vasculature: From descriptive heterogeneity to functional pathophysiology.Science357: eaal2379.

[21]. Ye Z et al.(2009). Increased CYP4B1 mRNA Is Associated with the Inhibition of Dextran Sulfate Sodium–Induced Colitis by Caffeic Acid in Mice.Experimental Biology and Medicine,234(6):605–616.

[22]. Zheng W et al.(2006). Evaluation of AGR2 and AGR3 as candidate genes for inflammatory bowel disease.Genes Immun.,7:11–18.

[23]. Yamada K et al.(2021). E7386,a Selective Inhibitor of the Interaction between β-Catenin and CBP Exerts Antitumor Activity in Tumor Models with Activated Canonical Wnt Signaling.Cancer Research,81(4):1052–1062.

[24]. Han B et al.(2020).YTHDF1-mediated translation amplifies Wnt-driven intestinal stemness.EMBO Reports,21(4).

[25]. Li Q et al.(2020).Lats1/2 Sustain Intestinal Stem Cells and Wnt Activation through TEAD-Dependent and Independent Transcription.Cell Stem Cell,26(5):675-692.e8.

[26]. Barker N et al.(2008).Crypt stem cells as the cells-of-origin of intestinal cancer.Nature,457(7229):608–611.

[27]. Crosnier C et al.(2006). Organizing cell renewal in the intestine: stem cells,sigals,and combinatorial control.Nat.Rev.Genet.,7:349–359.

[28]. Grinat J et al.(2020). The epigenetic regulator Mll1 is required for Wnt-driven intestinal tumorigenesis and cancer stemness.Nature Communications,11(1).

[29]. Beumer J et al.(2018).Enteroendocrine cells switch hormone expression along the crypt-to-villus BMP signalling gradient.Nat.Cell Biol.,20:909–916.

[30]. Halpern K.B et al.(2020)Lgr5+ telocytes are a signaling source at the intestinal villus tip.Nature Communications,11(1).

[31]. Liao H et al.(2020)A PROTAC peptide induces durable β-catenin degradation and suppresses Wnt-dependent intestinal cancer.Cell Discovery,6(1).

Cite this article

Wu,Z. (2025).Wnt/β-Catenin Signaling in Intestinal Cancers: Mechanisms, Therapeutic Targets, and Treatment Strategies.Theoretical and Natural Science,90,68-75.

Data availability

The datasets used and/or analyzed during the current study will be available from the authors upon reasonable request.

Disclaimer/Publisher's Note

The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of EWA Publishing and/or the editor(s). EWA Publishing and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content

About volume

Volume title: Proceedings of ICMMGH 2025 Workshop: Computational Modelling in Biology and Medicine

Conference website: https://2025.icmmgh.org/
ISBN:(Print) / (Online)
Conference date: 10 January 2025
Editor:Sheiladevi Sukumaran, Roman Bauer
Series: Theoretical and Natural Science
Volume number: Vol.90
ISSN:2753-8818(Print) / 2753-8826(Online)

© 2024 by the author(s). Licensee EWA Publishing, Oxford, UK. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license. Authors who publish this series agree to the following terms:
1. Authors retain copyright and grant the series right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this series.
2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the series's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this series.
3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See Open access policy for details).